- Home
- AYRO vs ENVB Comparison
AYRO vs ENVB Comparison
Compare AYRO & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- ENVB
- Stock Information
- Founded
- AYRO 2017
- ENVB 1994
- Country
- AYRO United States
- ENVB United States
- Employees
- AYRO N/A
- ENVB N/A
- Industry
- AYRO Telecommunications Equipment
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- ENVB Health Care
- Exchange
- AYRO Nasdaq
- ENVB Nasdaq
- Market Cap
- AYRO 3.6M
- ENVB 3.1M
- IPO Year
- AYRO N/A
- ENVB N/A
- Fundamental
- Price
- AYRO $6.38
- ENVB $1.32
- Analyst Decision
- AYRO
- ENVB Strong Buy
- Analyst Count
- AYRO 0
- ENVB 1
- Target Price
- AYRO N/A
- ENVB $10.00
- AVG Volume (30 Days)
- AYRO 45.1K
- ENVB 110.9K
- Earning Date
- AYRO 08-14-2025
- ENVB 08-11-2025
- Dividend Yield
- AYRO N/A
- ENVB N/A
- EPS Growth
- AYRO N/A
- ENVB N/A
- EPS
- AYRO N/A
- ENVB N/A
- Revenue
- AYRO $5,426.00
- ENVB N/A
- Revenue This Year
- AYRO N/A
- ENVB N/A
- Revenue Next Year
- AYRO N/A
- ENVB N/A
- P/E Ratio
- AYRO N/A
- ENVB N/A
- Revenue Growth
- AYRO N/A
- ENVB N/A
- 52 Week Low
- AYRO $5.17
- ENVB $1.01
- 52 Week High
- AYRO $15.28
- ENVB $11.55
- Technical
- Relative Strength Index (RSI)
- AYRO 47.80
- ENVB 57.52
- Support Level
- AYRO $6.80
- ENVB $1.19
- Resistance Level
- AYRO $7.19
- ENVB $1.28
- Average True Range (ATR)
- AYRO 0.97
- ENVB 0.06
- MACD
- AYRO -0.01
- ENVB 0.02
- Stochastic Oscillator
- AYRO 45.70
- ENVB 91.48
About AYRO AYRO Inc.
AYRO Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.